Dxcover Multi-Omic Cancer Early Detection Platform Recognized by Academy of Diagnostics & Laboratory Medicine for Scientific Excellence
31 Julio 2024 - 6:57AM
Business Wire
Distinguished Abstract Award to be presented
Wednesday July 31 at ADLM Annual Meeting
Dxcover Limited, a clinical-stage diagnostics company pioneering
its multi-omic spectral analysis (MOSA-Dx™) for early detection of
solid tumor cancers, will present its latest clinical evidence as a
Distinguished Abstract at the Academy of Diagnostics &
Laboratory Medicine Annual Meeting in Chicago July 28 – August 1,
2024.
Dxcover’s abstract entitled “Multi-omic blood test for early
detection of cancer and pre-cancer” is one of only 29 submissions
the Academy of Diagnostics & Laboratory Medicine Fellows
selected for scientific excellence from a pool of more than 775
abstracts accepted for ADLM 2024 (formerly the AACC Annual
Scientific Meeting & Clinical Lab Expo). Winning abstracts will
display the Academy blue ribbon during the ADLM 2024 poster
sessions.
President and Chief Executive Officer Professor Matthew J. Baker
PhD will present the abstract July 31 9:30am – 5:00pm CT in the
Poster Hall. “We are honored that our work has been recognized with
a Distinguished Abstract Award by the Academy. We will showcase how
our novel approach enables highly accurate early cancer and
pre-cancer detection to improve patient outcomes. The Dxcover
approach provides a low barrier for integration of our multi-omic
blood test into existing pathways as the technology is rapid,
simple to use, cost-effective and has minimal sample
preparation."
The company is establishing its US operations while
collaborating with US clinicians and healthcare sites to
demonstrate the Dxcover® PANAROMIC™ platform for early detection
capabilities in solid tumor cancers, including advanced
adenoma/colorectal, brain, lung, breast, pancreatic, kidney, liver
and others. The turn-key workflow of the Drop.Dry.Detect.® platform
enables rapid turnaround of accurate cancer detection results
within same day of specimen receipt.
About Dxcover Limited
The Dxcover PANAROMIC platform utilizes multi-omic spectral
analysis to detect cancer. This technology goes beyond traditional
liquid biopsy methods by analyzing signals missed by current
cell-free DNA testing. Dxcover's PANAROMIC platform has achieved
impressive results, including 99% specificity for early-stage
tumors and validation in over 3,000 patient samples across various
cancers. This versatile platform can be adapted for high
sensitivity (ruling out cancer) or high specificity (ruling in
cancer), making it a valuable tool for clinicians, pharmaceutical
and biotechnology cancer researchers and oncology diagnostic
platforms. Additionally, Dxcover's platform is patented in the US,
EU, and China. The company was recently incorporated in the US and
is establishing US operations in Nashville TN.
For further information https://www.dxcover.com/science
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731290666/en/
Stacy Chick stacy.chick@dxcover.com